Document Type : Original Article
Authors
- Lakshminarayanapuram Gopal Viswanathan 1
- Madhu Nagappa 2
- Doniparthi Seshagiri 1
- Jitender Saini 3
- Rose Dawn Bharath 3
- Karthik Kulanthaivelu 3
- Arun B Taly 4
- Sanjib Sinha 4
1 NIMHANS, Bangalore
2 Department of Neurology
3 Department of Neuroimaging and Interventional Radiology
4 Department of Neurology, NIMHANS
Abstract
Background: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a rare neurodegenerative disorder characterized by early-onset cerebellar ataxia, spasticity, and distal amyotrophy. This descriptive retrospective case series focuses on patients with ARSACS from the Indian subcontinent, with disease durations exceeding 10 years.
Methods: This case series included patients with typical clinical features of ARSACS who were evaluated in a single neurology unit between 2016 and 2022. Data on age at onset, illness duration at the last follow-up, and clinical manifestations were recorded. Electrophysiology reports, neuroimaging findings, and genetic testing results were reviewed. Functional disability documented at the last available clinical evaluation was recorded.
Results: The study comprised eight Indian patients with ARSACS [male/female (M:F) = 5:3] from unrelated families. The age at onset was between 2-5 years of age, with walking difficulties being the initial symptom in all cases. The correct diagnosis was established after the first decade of life, with a mean age at diagnosis of 23 years (range: 17-30 years) and a mean time to diagnosis of 20 years (range: 14-27 years). Electrophysiological studies showed demyelinating sensorimotor neuropathy. Imaging revealed characteristic linear T2-hypointensities in the pons and cerebellar atrophy. Genetic testing identified novel homozygous sacsin molecular chaperone (SACS) gene variants.
Conclusion: This study provides valuable insights into the clinical and genetic features of ARSACS in the Indian subcontinent. The time taken to establish the diagnosis ranged from 14 to 27 years in this series. Recognizing characteristic clinical and imaging findings may facilitate earlier diagnosis. The identification of novel genetic variants further expands our understanding of ARSACS.
Keywords
Main Subjects
- Thiffault I, Dicaire MJ, Tetreault M, Huang KN, Demers-Lamarche J, Bernard G, et al. Diversity of ARSACS Mutations in French-Canadians. Can J of Neurol Sci 2013; 40(1): 61-6.
- Martin MH, Bouchard JP, Sylvain M, St-Onge O, Truchon S. Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: A Report of MR Imaging in 5 Patients. AJNR Am J Neuroradiol 2007; 28(8): 1606-8.
- Pedroso JL, Braga-Neto P, Abrahão A, Rivero RLM, Abdalla C, Abdala N, et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): Typical clinical and neuroimaging features in a Brazilian family. Arq Neuropsiquiatr 2011; 69(2B): 288-91.
- Bouchard JP, Richter A, Mathieu J, Brunet D, Hudson TJ, Morgan K, et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Neuromuscul Disord 1998; 8(7): 474-9.
- Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012; 366(7): 636-46.
- Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): Expanding the genetic, clinical, and imaging spectrum. Orphanet J Rare Dis 2013; 15(8): 41.
- Bouhlal Y, Amouri R, El Euch-Fayeche G, Hentati F. Autosomal recessive spastic ataxia of Charlevoix-Saguenay: an overview. Parkinsonism Relat Disord 2011; 17(6): 418-22.
- Engert JC, Bérubé P, Mercier J, Doré C, Lepage P, Ge B, et al. ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000; 24(2): 120-5.
- Vermeer S, van de Warrenburg BP, Kamsteeg EJ, Brais B, Synofzik M. ARSACS. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [updated 2020 Jan 2]. Available from: http://pubmed.ncbi.nlm.nih.gov/20301432/
- van Lint M, Hoornaert K, Ten Tusscher MPM. Retinal nerve fiber layer thickening in ARSACS carriers. J Neurol Sci 2016; 370: 119-22.
- Bchetnia M, Bouchard L, Mathieu J, Campeau PM, Morin C, Brisson D, et al. Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability. J Med Genet 2021; 58(10): 653-65.
- Gentil BJ, Lai GT, Menade M, Larivière R, Minotti S, Gehring K, et al. Sacsin, mutated in the ataxia ARSACS, regulates intermediate filament assembly and dynamics. FASEB J 2019; 33(2): 2982-94.
- Agarwal PA, Ate-Upasani P, Ramprasad VL. Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)–First Report of Clinical and Imaging Features from India, and a Novel SACS Gene Duplication. Mov Disord Clin Pract 2017; 4(5): 775-7.
- Kuchay RAH, Mir YR, Zeng X, Hassan A, Musarrat J, Parwez I, et al. ARSACS as a Worldwide Disease: Novel SACS Mutations Identified in a Consanguineous Family from the Remote Tribal Jammu and Kashmir Region in India. Cerebellum 2019; 18(4): 807-12.
)